Physician profile
Tania E Cortas
NPI 1720293608
$33,144.87
in general payments reported to CMS, 2019-2025
87 companies · $2,376 in 2025
The $2,376 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,665 · 2020: $2,862 · 2021: $6,492 · 2022: $4,070 · 2023: $7,621 · 2024: $5,059 · 2025: $2,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $2,498 · Long Term Medical Supply Or Device Loan: $250 · Education: $11.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,297.01 |
| Consulting Fee | $2,497.50 |
| Long Term Medical Supply Or Device Loan | $249.99 |
| Education | $11.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,534.97 | 2019-2025 | Venclexta |
| Pfizer INC. | $4,302.44 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $4,090.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,219.77 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $1,454.36 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $1,163.47 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $1,028.58 | 2021-2025 | Enhertu, Injectafer, Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $969.75 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Janssen Biotech, INC. | $869.98 | 2020-2025 | Darzalex, Erleada, Imbruvica |
| Genzyme Corporation | $778.45 | 2019-2025 | |
| Genentech USA, INC. | $774.95 | 2019-2025 | Tecentriq, Alecensa, Gavreto |
| Lilly USA, LLC | $671.90 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $666.28 | 2019-2025 | Cabometyx |
| Amgen INC. | $621.82 | 2019-2023 | Kyprolis, Nplate, Vectibix |
| Incyte Corporation | $539.64 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
Show all 87 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $493.67 | 2019-2024 | |
| Seagen INC. | $406.47 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Gilead Sciences, INC. | $329.21 | 2019-2025 | Trodelvy |
| Emd Serono, INC. | $317.00 | 2019-2024 | Bavencio, Tepmetko |
| Karyopharm Therapeutics INC. | $315.21 | 2022-2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $290.68 | 2019-2025 | Fruzaqla, Iclusig, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $278.39 | 2019-2025 | |
| Blueprint Medicines Corporation | $254.31 | 2022-2025 | Ayvakit |
| Springworks Therapeutics, INC. | $236.58 | 2024-2025 | Ogsiveo |
| Sumitomo Pharma America, INC. | $229.42 | 2023-2025 | Orgovyx |
| Glaxosmithkline, LLC. | $225.11 | 2021-2025 | Zejula, Ojjaara, Jemperli |
| Astellas Pharma US INC | $210.79 | 2019-2024 | Xospata, Xtandi, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $192.81 | 2019-2023 | Imbruvica, Epkinly |
| Genmab U.S., INC. | $181.76 | 2023-2025 | Epkinly, Tivdak |
| Array Biopharma INC | $180.96 | 2021-2024 | Braftovi, Mektovi, Lorbrena |
| Tersera Therapeutics LLC | $159.94 | 2022-2025 | Zoladex, Quzyttir |
| Ipsen Biopharmaceuticals, INC | $154.69 | 2021-2025 | Onivyde, Somatuline Depot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.92 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $133.95 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacosmos Therapeutics INC. | $125.63 | 2022-2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $123.78 | 2019-2023 | Libtayo |
| Beigene USA, INC. | $123.41 | 2023-2025 | Brukinsa, Tevimbra |
| Adc Therapeutics America, INC. | $120.73 | 2021-2024 | |
| Galvanize Therapeutics, INC | $119.93 | 2024 | Aliya System |
| Jazz Pharmaceuticals INC. | $115.17 | 2021-2023 | Zepzelca |
| Stemline Therapeutics INC. | $104.58 | 2023-2025 | Orserdu |
| Puma Biotechnology, INC. | $102.65 | 2019-2024 | Nerlynx |
| Intuitive Surgical, INC. | $99.40 | 2025 | |
| Morphosys, US INC. | $81.24 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $76.33 | 2019-2025 | Pyrukynd |
| Amag Pharmaceuticals, INC. | $73.58 | 2019-2021 | |
| Adaptive Biotechnologies Corporation | $71.28 | 2024 | Clonoseq |
| Kyowa Kirin, INC. | $70.11 | 2021-2025 | Poteligeo |
| Servier Pharmaceuticals LLC | $68.87 | 2022-2024 | |
| Deciphera Pharmaceuticals INC. | $68.06 | 2023-2025 | Qinlock |
| Alexion Pharmaceuticals, INC. | $62.19 | 2019-2023 | Ultomiris |
| Kite Pharma, INC. | $60.53 | 2021-2024 | Yescarta |
| Progenics Pharmaceuticals, INC. | $48.68 | 2024-2025 | |
| Sobi, INC | $47.63 | 2025 | |
| Pharmaessentia USA Corporation | $46.12 | 2022-2025 | Besremi |
| Azurity Pharmaceuticals, INC. | $45.63 | 2024-2025 | Vivimusta, Danziten |
| Cti Biopharma Corp. | $42.77 | 2023 | Vonjo |
| Recordati_rare_diseases_inc. | $42.71 | 2024-2025 | Sylvant, Enjaymo |
| Lexicon Pharmaceuticals, INC. | $42.05 | 2020 | |
| Emmaus Medical, INC. | $39.46 | 2021-2022 | |
| Tesaro, INC. | $39.20 | 2019 | |
| Clovis Oncology, INC. | $38.34 | 2021 | |
| Acrotech Biopharma INC. | $37.71 | 2021-2025 | Beleodaq |
| Abbott Laboratories | $37.05 | 2022-2023 | Proclaim |
| Epizyme, INC. | $36.33 | 2022 | |
| Myriad Genetic Laboratories, INC. | $35.16 | 2021 | |
| Alnylam Pharmaceuticals INC. | $35.02 | 2023-2024 | Givlaari |
| Geron Corporation | $33.92 | 2025 | Rytelo |
| Global Blood Therapeutics, INC. | $33.47 | 2021-2022 | |
| Boston Scientific Corporation | $29.56 | 2022 | |
| Sun Pharmaceutical Industries INC. | $29.25 | 2022-2023 | Odomzo, Yonsa |
| Dendreon Pharmaceuticals LLC | $27.40 | 2025 | Provenge |
| Beone Medicines USA, INC. | $26.41 | 2025 | Tevimbra |
| Mirati Therapeutics, INC. | $26.35 | 2023 | Krazati |
| Fennec Pharmaceuticals, INC. | $25.45 | 2025 | Fyarro |
| Taiho Oncology, INC. | $22.13 | 2025 | |
| G1 Therapeutics, INC. | $21.62 | 2022 | |
| Secura Bio, INC. | $21.11 | 2023 | Copiktra |
| Heron Therapeutics, INC. | $20.48 | 2022 | |
| Novocure INC. | $17.85 | 2025 | Optune Lua (Novottf-200t) |
| Eusa Pharma (US) LLC | $17.61 | 2021 | |
| Chiesi USA, INC. | $17.25 | 2024 | Ferriprox |
| Myovant Sciences INC. | $15.71 | 2022 | |
| Advanced Accelerator Applications | $14.65 | 2019 | |
| Sirtex Medical INC | $13.60 | 2019 | |
| Accord Healthcare, INC. | $12.96 | 2022 | |
| Dova Pharmaceuticals | $12.20 | 2021 |
Drugs and devices associated with these payments
Imfinzi $2,594Keytruda $650Cabometyx $617Enhertu $567Reblozyl $413Orgovyx $396Imbruvica $376Opdivo $370Verzenio $361Xtandi $307Lenvima $295Injectafer $291Epkinly $255Ogsiveo $237Xpovio $230Venclexta $226Comirnaty $222Elrexfio $219Lynparza $218Ayvakit $215Tukysa $214Jaypirca $189Talzenna $186Pomalyst $185Retevmo $184Ibrance $183Jakafi $170Darzalex $163Adcetris $157Tecentriq $153Monjuvi $153Pemazyre $153Inlyta $143Trodelvy $138Gavreto $123Tavalisse $120Rezlidhia $120Aliya System $120Opdualag $120Erleada $120Welireg $119Onivyde $117Bavencio $114Tecvayli $113Altuviiio $110Mektovi $110Braftovi $110Padcev $108Paxlovid $107Monoferric $107Orserdu $105Zoladex $104Oxbryta $104Enjaymo $101Kisqali $99.75Rozlytrek $99.65Alecensa $99.65Da Vinci Surgical System $99.40Pluvicto $97.08Bosulif $93.62Zejula $90.93Vonjo $90.40Alprolix $83.09Cablivi $82.75Brukinsa $81.00Lorbrena $76.32Ojjaara $74.27Nubeqa $74.11Carvykti $73.02Stivarga $71.99Vitrakvi $71.99Polivy $71.42Clonoseq $71.28Tevimbra $68.82Fruzaqla $68.23Qinlock $68.06Kyprolis $66.76Sarclisa $65.63Jevtana $64.61Zepzelca $62.74Rybrevant $58.68Xospata $58.47Iclusig $56.73Piqray $56.66Phesgo $56.62Scemblix $56.19Xofigo $54.43Talvey $54.42Tivdak $53.43Jemperli $49.84Pylarify $48.68Lunsumio $47.17Somatuline Depot $46.00Mekinist $45.04Vectibix $44.39Xgeva $44.39Nplate $44.39Xalkori $41.83Fabhalta $40.45Tasigna $40.33
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tania Cortas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.